TR201901929T4 - TGFBeta'ya antikorlar. - Google Patents

TGFBeta'ya antikorlar. Download PDF

Info

Publication number
TR201901929T4
TR201901929T4 TR2019/01929T TR201901929T TR201901929T4 TR 201901929 T4 TR201901929 T4 TR 201901929T4 TR 2019/01929 T TR2019/01929 T TR 2019/01929T TR 201901929 T TR201901929 T TR 201901929T TR 201901929 T4 TR201901929 T4 TR 201901929T4
Authority
TR
Turkey
Prior art keywords
antibody molecules
antibody
igg4
igg1
bind
Prior art date
Application number
TR2019/01929T
Other languages
English (en)
Inventor
R Ledbetter Steven
P Hart Celia
G Holgate Robert
U Jermutus Lutz
L Buchanan Catriona
R Duncan Alexander
K Finch Donna
Original Assignee
Genzyme Corp
Optein Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp, Optein Inc filed Critical Genzyme Corp
Publication of TR201901929T4 publication Critical patent/TR201901929T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Mevcut buluş, antikor molekülleri, özellikle Dönüştürücü Büyüme Faktörü beta'yı (TGFß) bağlayan antikor molekülleri ve bunların kullanımları ile ilgilidir. Daha özel olarak, buluş, "pan-spesifik" antikor moleküllerini denilen TGFß1, TGFß2 ve TGFß3'ü bağlayan ve tercih edildiği üzere bunları nötralize eden antikor molekülleri ve bu tür antikor moleküllerinin kullanımları ile ilgilidir. Mevcut buluş içerisinde tercih edilen düzenlemeler, antikorun tamamı (örneğin, IgGl veya IgG4 gibi IgG) veya antikor fragmanları (örneğin, scFv, Fab, dAb) olarak antikor molekülleridir.
TR2019/01929T 2005-02-08 2006-02-08 TGFBeta'ya antikorlar. TR201901929T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65134305P 2005-02-08 2005-02-08

Publications (1)

Publication Number Publication Date
TR201901929T4 true TR201901929T4 (tr) 2019-03-21

Family

ID=36793677

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/01929T TR201901929T4 (tr) 2005-02-08 2006-02-08 TGFBeta'ya antikorlar.

Country Status (20)

Country Link
US (11) US7723486B2 (tr)
EP (2) EP3520815B1 (tr)
JP (5) JP5174466B2 (tr)
CN (3) CN101163502A (tr)
AU (1) AU2006213875B2 (tr)
BR (1) BRPI0607639B1 (tr)
CA (2) CA2597098C (tr)
CY (1) CY1121424T1 (tr)
DK (1) DK1850873T3 (tr)
ES (2) ES2905923T3 (tr)
HK (2) HK1201859A1 (tr)
HU (1) HUE042689T2 (tr)
IL (3) IL184995A (tr)
LT (1) LT1850873T (tr)
MX (1) MX2007009545A (tr)
PL (2) PL1850873T3 (tr)
PT (2) PT3520815T (tr)
SI (1) SI1850873T1 (tr)
TR (1) TR201901929T4 (tr)
WO (1) WO2006086469A2 (tr)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563874B2 (en) * 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
RU2386638C2 (ru) * 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
WO2006086469A2 (en) 2005-02-08 2006-08-17 Genzyme Corporation Antibodies to tgfbeta
DK2083863T3 (da) 2006-10-03 2015-06-22 Genzyme Corp Antistoffer mod tgf-beta til anvendelse til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi
EP2059534B1 (en) * 2007-02-23 2012-04-25 Schering Corporation Engineered anti-il-23p19 antibodies
SG178804A1 (en) 2007-02-23 2012-03-29 Schering Corp Engineered anti-il-23p19 antibodies
CA2680741A1 (en) 2007-03-22 2009-01-15 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
EP2313434A4 (en) 2008-07-31 2013-03-27 Univ California NEUTRALIZING ANTIBODIES OF BOTULINIC NEUROTOXINS
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
TWI614267B (zh) 2009-05-13 2018-02-11 建新公司 抗人類ｃｄ５２免疫球蛋白
SI3345615T1 (sl) 2010-03-01 2020-03-31 Bayer Healthcare Llc Optimizirana monoklonska protitelesa proti zaviralcu poti tkivnega faktorja (TFPI)
SI2835053T1 (sl) 2010-03-12 2016-09-30 Genzyme Corporation Kombinirana terapija za zdravljenje raka dojke
WO2012047427A2 (en) 2010-08-31 2012-04-12 The Regents Of The University Of California Antibodies for botulinum neurotoxins
SG187953A1 (en) * 2010-09-01 2013-03-28 Genzyme Corp Treatment of myocardial infarction using tgf - beta antagonists
RU2018102375A (ru) 2010-11-18 2019-02-21 Зе Дженерал Хоспитал Корпорейшен Новые композиции и применения антигипертензивных средств для терапии рака
PE20140633A1 (es) 2010-11-19 2014-05-30 Eisai Randd Man Co Ltd Anticuerpos neutralizadores anti-ccl20
SI2714735T1 (sl) * 2011-06-03 2021-12-31 Xoma Technology Ltd. Protitelesa, specifična za TGF-beta
EP2737083A1 (en) 2011-07-27 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Scientifique) Methods for diagnosing and treating myhre syndrome
AU2011379972B2 (en) 2011-10-26 2016-05-12 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
US9782452B2 (en) 2011-11-22 2017-10-10 Cornell University Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling
ES2694203T3 (es) 2012-03-08 2018-12-19 Ludwig Institute For Cancer Research Limited Anticuerpos específicos del Tgf-1 y métodos y usos de los mismos
BR112014022200A2 (pt) 2012-03-08 2019-09-24 Selig Sealing Products Inc membro de vedação de recipiente com compodnente de segurança protegido e aba de remoção
RU2681502C2 (ru) * 2013-03-11 2019-03-06 Джензим Корпорейшн Сконструированные анти-tgf-бета антитела и антиген-связывающие фрагменты
HUE057521T2 (hu) 2013-03-14 2022-05-28 Brigham & Womens Hospital Inc Készítmények és eljárások epithelialis õssejtek szaporítására és tenyésztésére
MY172324A (en) * 2013-03-20 2019-11-21 Genzyme Corp Methods for treating osteogenesis imperfecta
PL2981822T3 (pl) 2013-05-06 2021-07-12 Scholar Rock, Inc. Kompozycje i sposoby modulacji czynnika wzrostu
WO2015027082A1 (en) 2013-08-22 2015-02-26 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
ES2739203T3 (es) * 2014-05-16 2020-01-29 Wellhead Biological Tech Corp Uso del ginsenósido M1 para la inhibición de la fibrosis renal
EP3189134A1 (en) 2014-09-03 2017-07-12 The Brigham and Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
AU2015333687B2 (en) 2014-10-14 2021-03-18 Dana-Farber Cancer Institute, Inc. Antibody molecules to PD-L1 and uses thereof
CA2971186A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
EP3240805A4 (en) 2014-12-15 2018-05-09 The Regents of the University of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
CN107530423B (zh) 2015-01-14 2022-04-05 布里格姆及妇女医院股份有限公司 用抗lap单克隆抗体治疗癌症
EP3277716B1 (en) 2015-04-03 2020-06-24 XOMA Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
EP3307772B1 (en) 2015-06-12 2020-09-09 Ludwig Institute For Cancer Research Limited Tgf-beta 3 specific antibodies and methods and uses thereof
TW201718010A (zh) * 2015-06-19 2017-06-01 健臻公司 治療原發性局部節段性腎小球硬化症之方法
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
PT3317301T (pt) 2015-07-29 2021-07-09 Novartis Ag Terapias de associação compreendendo moléculas de anticorpo contra lag-3
AU2016301380B2 (en) 2015-08-04 2021-07-01 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
WO2017075433A1 (en) * 2015-10-30 2017-05-04 The Regents Of The University Of California Transforming growth factor-beta-responsive polypeptides and their methods for use
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
WO2017106630A1 (en) 2015-12-18 2017-06-22 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
EP3400286A1 (en) 2016-01-08 2018-11-14 Massachusetts Institute Of Technology Production of differentiated enteroendocrine cells and insulin producing cells
RU2018130106A (ru) * 2016-01-21 2020-02-21 Дзе Скриппс Рисерч Инститьют Вакцина против синтетических опиоидов
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
ES2951648T3 (es) 2016-03-11 2023-10-24 Scholar Rock Inc Inmunoglobulinas de unión a Tgfbeta1 y uso de las mismas
MX2018014047A (es) 2016-05-17 2019-06-20 Genentech Inc Firmas de genes estromales para el diagnóstico y uso en inmunoterapia.
GB201610044D0 (en) * 2016-06-08 2016-07-20 Ucb Biopharma Sprl Antibodies
JP2019533003A (ja) * 2016-08-11 2019-11-14 プレシセラ，インコーポレイテッド ＴＧＦ−βアンタゴニストコンジュゲート
KR20190057308A (ko) 2016-09-02 2019-05-28 더 리전츠 오브 더 유니버시티 오브 캘리포니아 인터류킨-6 수용체 알파-결합 단일 사슬 가변 단편을 포함하는 방법 및 조성물
WO2018043734A1 (en) * 2016-09-05 2018-03-08 Chugai Seiyaku Kabushiki Kaisha Anti-tgf-beta 1 antibodies and methods of use
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3048220A1 (en) 2016-12-30 2018-07-05 Frequency Therapeutics, Inc. 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
US20180207267A1 (en) 2017-01-06 2018-07-26 Scholar Rock, Inc. Isoform-specific, context-permissive tgfb1 inhibitors and use thereof
AR110755A1 (es) 2017-01-20 2019-05-02 Genzyme Corp Anticuerpos dirigidos a hueso
WO2018134681A1 (en) 2017-01-20 2018-07-26 Sanofi Anti-tgf-beta antibodies and their use
TW202313678A (zh) 2017-01-20 2023-04-01 法商賽諾菲公司 抗TGF-β抗體及其用途
US11021527B2 (en) 2017-05-04 2021-06-01 Acceleron Pharma Inc. Transforming growth factor beta receptor type II fusion polypeptides
WO2018237157A1 (en) 2017-06-22 2018-12-27 Novartis Ag CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
JP2021502066A (ja) 2017-11-06 2021-01-28 ジェネンテック， インコーポレイテッド がんの診断及び療法
AU2018368731A1 (en) 2017-11-16 2020-05-14 Novartis Ag Combination therapies
US20200371091A1 (en) 2017-11-30 2020-11-26 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
CA3093468A1 (en) 2018-03-09 2019-09-12 Agenus Inc. Anti-cd73 antibodies and methods of use thereof
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
PE20210320A1 (es) 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
AU2019301283A1 (en) * 2018-07-10 2021-02-04 Sanofi Combination therapies against cancer targeting CD38 and TGF-beta
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
SI3677278T1 (sl) 2018-07-11 2022-01-31 Scholar Rock, Inc. Izoformno selektivni zaviralci TGFBETA1 in uporaba le-teh
TW202019957A (zh) 2018-07-11 2020-06-01 美商供石公司 TGFβ1抑制劑及其用途
US20210122814A1 (en) 2018-07-11 2021-04-29 Scholar Rock, Inc. HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
US11162071B2 (en) 2018-08-17 2021-11-02 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating JAG-1
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
CN113164780A (zh) 2018-10-10 2021-07-23 泰洛斯治疗公司 抗lap抗体变体及其用途
CA3118186A1 (en) 2018-11-05 2020-05-14 Ludwig Institute For Cancer Research Ltd Humanized and variant tgf-.beta.1 specific antibodies and methods and uses thereof
WO2020095104A1 (en) 2018-11-05 2020-05-14 Ludwig Institute For Cancer Research Ltd. HUMANIZED AND VARIANT TGF-β3 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
WO2020106750A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
BR112021011874A2 (pt) 2018-12-20 2021-09-08 Novartis Ag Regime de dosagem e combinação farmacêutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
EA202192130A1 (ru) 2019-01-30 2021-12-28 Сколар Рок, Инк. Специфичные к ltbp-комплексу ингибиторы tgf и их применение
KR20210129672A (ko) 2019-02-15 2021-10-28 노파르티스 아게 치환된 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도
MX2021009763A (es) 2019-02-15 2021-09-08 Novartis Ag Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
AU2020322474A1 (en) * 2019-08-01 2022-03-10 Vaccinex,Inc. Combined inhibition of semaphorin-4D and TGFβ and compositions therefor
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
WO2021081258A1 (en) 2019-10-23 2021-04-29 Cue Biopharma, Inc. TGF-β POLYPEPTIDES
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置
CA3165399A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
BR112022013733A2 (pt) 2020-01-11 2022-11-01 Scholar Rock Inc Inibidores de tgfbeta e uso dos mesmos
CN117551194A (zh) 2020-03-19 2024-02-13 基因泰克公司 同种型选择性抗TGF-β抗体及使用方法
BR112022026202A2 (pt) 2020-06-23 2023-01-17 Novartis Ag Regime de dosagem compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022097060A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
AU2021388155A1 (en) 2020-11-25 2023-06-15 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
EP4284510A1 (en) 2021-01-29 2023-12-06 Novartis AG Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
CA3208365A1 (en) 2021-02-15 2022-08-18 Chantal KUHN Cell therapy compositions and methods for modulating tgf-b signaling
EP4294827A1 (en) 2021-02-19 2023-12-27 Theripion, Inc. Paraoxonase fusion polypeptides and related compositions and methods
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CN112940119B (zh) * 2021-04-26 2022-05-20 北京芳渟阳生生物科技有限公司 一种单克隆抗体及其与间充质干细胞外泌体的联合应用
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
IL310164A (en) 2021-08-11 2024-03-01 Hcw Biologics Inc Multichain chimeric polypeptides and their use in the treatment of liver diseases
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
US20230372444A1 (en) 2022-04-13 2023-11-23 HCW Biologics, Inc. Methods of reducing neuroinflammation
WO2023201310A1 (en) 2022-04-13 2023-10-19 HCW Biologics, Inc. Multi-chain chimeric polypeptide for use in the treatment of circardian clock gene disorder
WO2024077166A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating lung cancer
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2056642B (en) 1979-08-08 1983-05-11 Dawson Int Radio frequency drying of textile material
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0561921A1 (en) 1990-12-10 1993-09-29 Panama Engineering Pty Limited Fork-lift attachment
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
US5269388A (en) 1991-11-12 1993-12-14 Stress-Tek, Inc. Weighing bed
US5543143A (en) * 1992-03-06 1996-08-06 Corixa Corporation Method for activating macrophages/monocytes
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
WO1997029131A1 (en) 1996-02-09 1997-08-14 Basf Aktiengesellschaft HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)
CN1330377C (zh) 1996-03-10 2007-08-08 明治乳业株式会社 用于治疗***反应疾病的基于肽的免疫治疗剂
WO2000034784A1 (en) 1998-12-10 2000-06-15 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
TR200503572T2 (tr) * 1999-03-25 2006-04-21 Knoll Gmbh & Co. Kg. Beşeri IL-12'yi bağlayan beşeri antikorlar ve bunları üretmek için yöntemler.
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US7323311B2 (en) 2000-03-03 2008-01-29 Cambridge Antibody Technology Limited Methods of obtaining a specific binding member that binds eotaxin
US20030224501A1 (en) * 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
CN1323716C (zh) * 2000-12-06 2007-07-04 应用研究***Ars股份公司 Sarp－1在治疗和/或预防硬皮病中的应用
US7560558B2 (en) * 2002-08-23 2009-07-14 Kirin Beer Kabushiki Kaisha Compound having TGFβ inhibitory activity and medicinal composition containing the same
US20060286105A1 (en) * 2003-04-30 2006-12-21 Steven Ledbetter Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
WO2005010049A2 (en) 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
JP2005112812A (ja) * 2003-10-09 2005-04-28 Zeria Pharmaceut Co Ltd リン酸化部位特異的抗体及びそれを用いたスクリーニング方法
JP4842834B2 (ja) 2003-12-09 2011-12-21 ノボザイムス，インコーポレイティド 糸状菌株における遺伝子の発現を排除するか又は低めるための方法
RU2386638C2 (ru) * 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
KR100749566B1 (ko) * 2004-04-21 2007-08-16 이화여자대학교 산학협력단 Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
WO2006086469A2 (en) * 2005-02-08 2006-08-17 Genzyme Corporation Antibodies to tgfbeta
ITMI20110376A1 (it) 2011-03-10 2012-09-11 Wilic Sarl Aerogeneratore raffreddato a fluido
DE102011078333A1 (de) 2011-06-29 2013-01-03 Siemens Aktiengesellschaft Überspannungsableiter

Also Published As

Publication number Publication date
JP6463807B2 (ja) 2019-02-06
IL225752A0 (en) 2013-06-27
SI1850873T1 (sl) 2019-05-31
CA2597098C (en) 2016-08-02
IL184995A (en) 2013-04-30
JP6341945B2 (ja) 2018-06-13
JP2016128512A (ja) 2016-07-14
DK1850873T3 (en) 2019-03-18
US9090685B2 (en) 2015-07-28
EP3520815A1 (en) 2019-08-07
CY1121424T1 (el) 2020-05-29
ES2905923T3 (es) 2022-04-12
ES2711213T3 (es) 2019-04-30
BRPI0607639B1 (pt) 2022-04-05
CN104177497B (zh) 2018-01-16
JP2013031444A (ja) 2013-02-14
US8383780B2 (en) 2013-02-26
JP5174466B2 (ja) 2013-04-03
HK1201860A1 (en) 2015-09-11
US20190177406A1 (en) 2019-06-13
EP1850873A4 (en) 2012-06-13
US9481726B2 (en) 2016-11-01
US20150284456A1 (en) 2015-10-08
US20130243788A1 (en) 2013-09-19
MX2007009545A (es) 2008-03-11
EP1850873A2 (en) 2007-11-07
US10781252B2 (en) 2020-09-22
JP2015003917A (ja) 2015-01-08
IL225752A (en) 2017-10-31
US20140127230A1 (en) 2014-05-08
PL1850873T3 (pl) 2019-06-28
HK1201859A1 (en) 2015-09-11
CN104151427B (zh) 2017-09-08
EP1850873B1 (en) 2018-11-28
IL184995A0 (en) 2007-12-03
EP3520815B1 (en) 2021-11-17
HUE042689T2 (hu) 2019-07-29
PT3520815T (pt) 2022-02-02
US7723486B2 (en) 2010-05-25
CA2597098A1 (en) 2006-08-17
CN101163502A (zh) 2008-04-16
US20230078449A1 (en) 2023-03-16
US20060251658A1 (en) 2006-11-09
PL3520815T3 (pl) 2022-04-11
US20170066821A1 (en) 2017-03-09
IL255078B (en) 2021-01-31
AU2006213875B2 (en) 2010-08-19
US8591901B2 (en) 2013-11-26
BRPI0607639A2 (pt) 2009-09-22
JP2017217003A (ja) 2017-12-14
US20210061897A1 (en) 2021-03-04
US10174108B2 (en) 2019-01-08
CN104151427A (zh) 2014-11-19
IL255078A0 (en) 2017-12-31
WO2006086469A3 (en) 2007-04-19
CN104177497A (zh) 2014-12-03
WO2006086469A2 (en) 2006-08-17
US20070264255A1 (en) 2007-11-15
AU2006213875A1 (en) 2006-08-17
JP6005703B2 (ja) 2016-10-12
CA2930677A1 (en) 2006-08-17
LT1850873T (lt) 2019-04-10
US20110008364A1 (en) 2011-01-13
US20070134246A1 (en) 2007-06-14
JP5726140B2 (ja) 2015-05-27
JP2008529503A (ja) 2008-08-07
PT1850873T (pt) 2019-02-19

Similar Documents

Publication Publication Date Title
TR201901929T4 (tr) TGFBeta'ya antikorlar.
AU2018272852A8 (en) Antibodies comprising modified heavy constant regions
WO2006089133A8 (en) Anti-cd19 antibodies and uses in oncology
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
HRP20191462T1 (hr) Antitijela usmjerena protiv her-3 i njihove uporabe
WO2016081746A8 (en) Antibodies comprising modified heavy constant regions
EA201070695A1 (ru) Молекулы гуманизированных антител, специфичных к il-31
CY1116632T1 (el) Εξουδετερωτες αντισωματων του τελεστη διεγερσης αποικιων κοκκιοκυτταρων μακροφαγων ανθρωπου
CO6260104A2 (es) Anticuerpos contra la il-25
RS53760B1 (en) HUMAN ANTIBODIES RELATING TO MESOTELINE AND THEIR USES
PE20091342A1 (es) Inmunoglobulinas
PE20081899A1 (es) Anticuerpos anti-ige
WO2005016969A3 (en) Cd20-binding polypeptide compositions
DE602006013029D1 (de) Anti-egfr-antikörper
WO2006121852A3 (en) Anti-cd19 antibody therapy for autoimmune disease
CR20120587A (es) Moléculas de unión al antígeno que fijan egfr, vectores que las codifican y uso de las mismas
GEP20104922B (en) Antibodies to m-csf
EP2511301A3 (en) Human antibodies to ERBB2
UA92504C2 (en) Anti-myostatin monoclonal antibody
WO2006071441A3 (en) Antibodies directed to gpnmb and uses thereof
BRPI0607486A2 (pt) anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos
NZ597023A (en) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
RS54271B1 (en) HUMAN MONOCLONIC ANTIBODIES FOR LIGAND PROGRAMMED DEATH 1 (PD-L1)
SG196697A1 (en) Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
WO2006133450A3 (en) Anti-cd19 antibody therapy for the transplantation